Decision Coaching for Lung Cancer Screening
Trial Summary
What is the purpose of this trial?
Hypothesis 1a: The investigators anticipate that navigator decision coaching, compared to enhanced usual care (EUC) will result in higher quality SDM for lung cancer screening (LCS )(primary outcome), greater knowledge of lung cancer screening benefits and harms, and lower decisional conflict. Hypothesis 1b: Compared to enhanced usual care (EUC), we expect that TELESCOPE will result in more screening discussions, increased initial for lung cancer screening (LCS) with low-dose CT scan (LDCT) uptake among interested participants, increased adherence to repeat LCS and diagnostic testing, and increased smoking cessation referrals for current smokers. Hypothesis 2: The investigators expect that a "booster" coaching session will increase adherence to repeat lung cancer screening (LCS).
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the Remote Decision Coaching with Navigation Intervention for lung cancer screening?
Research shows that decision aids and coaching can help patients make better decisions by increasing their involvement and understanding, which is important for complex choices like lung cancer screening. Studies have found that patients using decision aids are more likely to participate in decision-making and make higher-quality decisions.12345
Is Decision Coaching for Lung Cancer Screening safe for humans?
How is the TELESCOPE treatment different from other lung cancer screening treatments?
The TELESCOPE treatment is unique because it involves remote decision coaching and navigation to support shared decision-making (a process where patients and healthcare providers make decisions together) for lung cancer screening, which is not commonly emphasized in traditional screening methods.16101112
Research Team
Anita Y Kinney, PhD, RN
Principal Investigator
Rutgers Cancer Institute
Eligibility Criteria
The TELESCOPE trial is for English-speaking adults aged 50-77 who have a significant smoking history (at least 20 pack-years) and are either current smokers or quit within the last 15 years. They must be due for a non-emergency medical visit but not pregnant, without lung cancer history, nor screened for it in the past year. Health providers involved need to work at participating sites.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants receive navigator decision coaching or enhanced usual care for lung cancer screening
Follow-up
Participants are monitored for adherence to lung cancer screening and smoking cessation referrals
Treatment Details
Interventions
- Remote Decision Coaching with Navigation Intervention
- TELESCOPE
Remote Decision Coaching with Navigation Intervention is already approved in United States for the following indications:
- Lung Cancer Screening Decision Support
Find a Clinic Near You
Who Is Running the Clinical Trial?
Rutgers, The State University of New Jersey
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
National Institutes of Health (NIH)
Collaborator